Printer Friendly

Epimutation and Cancer: Carcinogenesis Viewed as Error-Prone Inheritance of Epigenetic Information.

1. Introduction

Recently there has been considerable interest in the role of epigenetic mechanisms in cancer [1-3] and it has been proposed that deranged epigenetic regulation is the crucial lesion of carcinogenesis. Such a scenario would account for the many deviant characteristics exhibited by malignant and premalignant cells [4]. These include multiple derangements of structure and metabolism and the emergence of cellular properties associated with different tissues and with embryonic stages of development, especially the metastatic ability to transgress tissue barriers and migrate to distant sites which is the defining characteristic of malignant neoplasms.

The cardinal abnormality exhibited by the majority of adult cancers is chromosomal instability (CIN) with widespread alterations in gene expression [5] accompanied by a range of diagnostic cytological aberrations [6]. Thus, the fundamental lesion at the root of this pathological process must be one that causes a general disturbance of the chromatin pattern and it has been proposed that this results from a failure to preserve the epigenetic markers during DNA replication [7]. According to this proposal the primary (initiating) lesion of carcinogenesis is the acquisition of one or more mutations that result, during stem cell mitosis, in defective vertical transmission of the epigenetic pattern characteristic of the differentiated tissue. If the development of this defect was equally likely for each tissue it might be anticipated that the age-specific incidence of all cancers would be similar, but the statistical data show that there are substantial tissue-specific differences [8] and these require explanation.

2. Differences in Cancer Incidence in Different Tissues

Some of the relevant factors involve obvious differences such as the number of susceptible cells and the degree of mutagenic exposure. For each tissue the probability of the initiation phase taking place is influenced by the size of the population, the number of genes that have to be mutated to bring about the defect, the exposure to mutagenic events, and the elimination or repair efficiency of the relevant stem cells, i.e., stem cell numbers, the number of crucial genes, and their effective mutation rate [9, 10]. Differences in the mutation rate and/or exposure to mutagens have been proposed to account for the observed variation in cancer incidence in different tissues and these considerations have received much detailed attention in the extensive extant literature and are not addressed in any detail in this brief review. However the relative size and turnover of the stem cell population at risk in a tissue are obviously a determining factor.

An important question with regard to the epigenetic theory of carcinogenesis concerns the problem of which genes are necessary and sufficient to bring about the defective copying of the epigenetic pattern and whether the same genes are involved in all cases. It can be argued that in developmental neoplasms the underlying problem is the failure of evocation of some gene silencing mechanism involved in differentiation, and in these cases reversal is possible [11]. In adult malignancies there are many genes implicated in epigenetic copying that could be affected [12-16] and relatively little is known about the control of homologous gene silencing and the effect of ploidy. Also, the involvement of a ratifying system has been suggested, such as the p53, related DNA editing machinery [17-20]. At present the impact of these matters remains unresolved.

However, assuming that the initiation stage has been accomplished, the factors implicated in the secondary carcinogenic events, i.e., the failure of fidelity of epigenetic copying resulting from the initiating lesion, have hitherto received relatively little discussion. In essence the likelihood of the acquisition of epigenetic errors that result in malignancy will depend on two criteria: (1) the rate of stem cell proliferation and (2) the ease of activation of the genes that determine the metastatic phenotype. In the absence of clear evidence of which genes are involved in the processes that result in the manifestation of the malignant phenotype, the second factor is difficult to assess. Possibly, if reactivation of the most recently silenced genes occurs more readily, it might be speculated, for example, that migratory properties would be more likely to be expressed in melanocytes, thus accounting for the earlier age-specific incidence of melanoma [8]. An interesting correlation between the extent of DNA methylation and the age-specific risk of malignancy has been demonstrated [21] which may indicate that cell classes with a higher proportion of silenced genes are more susceptible to malignant transformation.

3. Significance of the Stem Cell Proliferation Rate

From the theoretical point of view, the proposed central role of stem cell proliferation in bringing about the epigenetic errors that lead to the malignant phenotype makes a number of testable predictions, several of which are known to be the case. For example, it follows that malignant tumours are not found in nonproliferating tissues such as the central nervous system and rarely occur in slowly proliferating cells such as striated muscle. Moreover, since the greatest turnover occurs in epithelia, it accounts for the high proportion of epithelial cancers. The central significance of stem cell proliferation has been emphasised by the statistical association between cancer risk and the total number of stem cell divisions in different tissues as shown by Tomasetti and Vogelstein [22] and the epigenetic model is compatible with the observed age-specific cancer incidence in a number of specific cases where the relevant data are available [23]. The importance of the stem cell proliferation rate also accounts for the decreased cancer incidence rate with increasing age. This phenomenon has been analysed by Pompei and Wilson [24] and shown to correspond with a linear age-specific reduction. Another interesting example of the effect of the rate of stem cell proliferation and cancer incidence is the relatively low incidence of melanoma in blacks which is inversely proportional to the degree of melanisation and has been ascribed to the diminished stem cell turnover in regions where melanocyte proliferation is inhibited by loss of cytoplasmic volume through melanosome donation to adjacent keratocytes [25].

Also consistent with the epigenetic model is the evidence of increased risk of malignancy associated with factors increasing the proliferation rate of tissues. This includes the stimulatory effects of chronic inflammation and specific growth factors such as hormones, e.g., the increased breast cancer risk associated with hormone replacement therapy [26]. At the other end of the spectrum is the explanation of the sometimes-observed prolonged induction periods by nonproliferation of transformed cells.

The influence of the stem cell proliferation rate on the acquisition of malignant characteristics importantly predicts that initiated cells can be prevented from becoming malignant by suppression of proliferation. This phenomenon has been described in the case of hepatocytes experimentally initiated by aflatoxin [27-30].

4. Preventative and Therapeutic Prospects

In brief, the preventative possibilities presented by the epimutation model of cancer concern the identification of mutant genes responsible for the error-prone epigenetic copying and their repair or selective elimination of cells bearing these mutations. In this respect the scenario differs from the conventional theories of carcinogenesis only in focusing on genes implicated in the epigenetic copying mechanism. It is a moot point which genes might be most significant in this respect but possible candidates include genes involved in regulating the activities of DNA methylases, histone deacetylases, p53 and related processes involved in apoptosis, and other possible gatekeeping and editing functions. For example, polycomb group proteins such as EZH2 the H3K29 methylase UTX and components of the chromatin remodelling complex such as SWI/SNF are modified in several cancers [31] and there is evidence that certain drugs targeting epigenetic mechanisms show clinical promise [32] but the picture is complicated by the fact that once epigenetic error is introduced, the genomic interactions will result in abnormal combinations of hypo- and hypermethylation [33] so that the outcome of epigenetic interference cannot be easily predicted and may differ according to the affected tissue or the individual [34].

Assuming that malignant behaviour in all cases is derived from a specific genetic composition, a promising approach might lie in the identification of the genes giving rise to the crucial malignant properties. This would potentially enable the design of agents causing epigenetic suppression of these malignant genes or drugs to selectively eliminate cells expressing those genes. At present, the nature of such crucial genetic targets is not clear and, moreover, it seems probable that the route to malignancy varies according to the tissue of origin. For the present it appears that the most accessible target is the evidence that the carcinogenic risk is a function of the stem cell proliferation rate of the tissue in question. Hence, if a tissue has undergone carcinogenic induction, any means that diminishes the rate of stem cell proliferation will suppress the emergence of a malignant variant clone and, of course, many of the currently effective chemotherapeutic agents target the proliferation rate of the affected tissue.

5. Conclusions

The epigenetic theory of carcinogenesis proposes that the acquisition of the malignant phenotype results from errorprone copying of the epigenetic pattern when tissue stem cells divide. This failure of fidelity of epigenetic transmission is due to initiating mutations affecting the set of crucial genes involved in the normally stable copying of the epigenetic pattern. The manifestation of error-prone epigenetic copying is the generation of clones showing a diversifying range of abnormalities including structural and functional anomalies, abnormal mitoses, alterations of ploidy, and the occurrence of bizarre cytological features. It is argued that these anomalies give rise to cells some of which exhibit malignant characteristics and are able to transgress tissue barriers and spread to distant sites.

Whilst it maybe impossible to avoid the initiating mutagenesis, in principle cancer could be prevented if cells bearing the initiating lesion(s) could be identified and the faulty epigenetic process corrected or the affected cells eliminated. This eventuality remains a hope for the future.

However, in view of the important role of mitosis in enabling the perpetuation of epigenetic errors, ensuring the minimum turnover rate of tissue stem cells seems to offer a basis for a general cancer prevention strategy.

Conflicts of Interest

The author declares that there are no conflicts of interest regarding the publication of this article.


The author is grateful to Professor Ferdy Lejeune for constructive comments and encouragement.


[1] P. A. Jones and S. B. Baylin, "The fundamental role of epigenetic events in cancer," Nature Reviews Genetics, vol. 3, no. 6, pp. 415-428, 2002.

[2] P. A. Jones and S. B. Baylin, "The epigenomics of cancer," Cell, vol. 128, no. 4, pp. 683-692, 2007.

[3] S. B. Baylin and P. A. Jones, "A decade of exploring the cancer epigenome--biological and translational implications," Nature Reviews Cancer, vol. 11, no. 10, pp. 726-734, 2011.

[4] P. Riley, "Cancer is the outcome of defective epigenetic copying of the pattern of selective gene activity in differentiated cells," Cancer Research Frontiers, vol. 1, no. 3, pp. 280-287, 2015.

[5] C. Lengauer, K. W. Kinzler, and B. Vogelstein, "Genetic instabilities in human cancers," Nature, vol. 396, no. 6712, pp. 643-649, 1998.

[6] M. M. Boddington and A. I. Spriggs, "Cytological Diagnosis of Cancer: Its Uses and Limitations," British Medical Journal, vol. 1, no. 5449, pp. 1523-1529, 1965.

[7] P. A. Riley, "Failure of fidelity of vertical transmission of epigenetic patterning as the basis of cancer," Melanoma Research, vol. 24, no. 5, pp. 424-427, 2014.

[8] Surveillance, Epidemiology and End Results (SEER) Program ( National Cancer Institute, DCCPS, Surveillance Research Program, released October 2016.

[9] P. Armitage and R. Doll, "The age distribution of cancer and a multi-stage theory of carcinogenesis," British Journal of Cancer, vol. 8, no. 1, pp. 1-12, 1954.

[10] P. Armitage, "Multistage models of carcinogenesis.," Environmental Health Perspectives, vol. 63, pp. 195-201, 1985.

[11] A. Bradley, M. Evans, M. H. Kaufman, and E. Robertson, "Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines," Nature, vol. 309, no. 5965, pp. 255-256, 1984.

[12] J. A. Law and S. E. Jacobsen, "Establishing, maintaining and modifying DNA methylation patterns in plants and animals," Nature Reviews Genetics, vol. 11, no. 3, pp. 204-220, 2010.

[13] T. M. Holm, L. Jackson-Grusby, T. Brambrink, Y. Yamada, W. M. Rideout III, and R. Jaenisch, "Erratum: Globalloss of imprinting leads to widespread tumorigenesis in adult mice (Cancer Cell (October 2005) 8 (275-285))," Cancer Cell, vol. 9, no. 1, p. 69, 2006.

[14] A. Miremadi, M. Z. Oestergaard, P. D. P. Pharoah, and C. Caldas, "Cancer genetics of epigenetic genes," Human Molecular Genetics, vol. 16, no. 1, pp. R28-R49, 2007.

[15] B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., and K. W. Kinzler, "Cancer genome landscapes," Science, vol. 340, no. 6127, pp. 1546-1558, 2013.

[16] D. J. Weisenberger and G. Liang, "Contributions of DNA methylation aberrancies in shaping the cancer epigenome," Translational Cancer Research, vol. 4, no. 3, pp. 219-234, 2015.

[17] H. Mizuno, B. T. Spike, G. M. Wahl, and A. J. Levine, "Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures," Proceedings of the National Acadamy of Sciences of the United States of America, vol. 107, no. 52, pp. 22745-22750, 2010.

[18] A. J. Levine and B. Greenbaum, "The maintenance of epigenetic states by p53: The guardian of the epigenome," Oncotarget, vol. 3, no. 12, pp. 1503-1504, 2012.

[19] P. A. J. Muller and K. H. Vousden, "P53 mutations in cancer," Nature Cell Biology, vol. 15, no. 1, pp. 2-8, 2013.

[20] K. I. Leonova, L. Brodsky, B. Lipchick et al., "p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs," Proceedings of the National Acadamy of Sciences of the United States of America, vol. 110, no. 1, pp. E89-E98, 2013.

[21] M. Klutstein, J. Moss, T. Kaplan, and H. Cedar, "Contribution of epigenetic mechanisms to variation in cancer risk among tissues," Proceedings of the National Acadamy of Sciences of the United States of America, vol. 114, no. 9, pp. 2230-2234, 2017.

[22] C. Tomasetti and B. Vogelstein, "Variation in cancer risk among tissues can be explained by the number of stem cell divisions," Science, vol. 347, no. 6217, pp. 78-81, 2015.

[23] P. A. Riley, "The epigenetic theory of carcinogenesis: Investigation of the model of age-specific incidence," PRAS Open, vol. 1, no. 1, pp. 1-6, 2017.

[24] F. Pompei, "Age distribution of cancer: The Incidence turnover at old age," Human and Ecological Risk Assessment (HERA), vol. 7, no. 6, pp. 1619-1650, 2001.

[25] P. A. Riley, "The influence of pigment transfer on the risk of developing melanoma: The significance of the melanocyte 'amputation cycle'," Journal of Analytical Oncology, vol. 5, no. 3, pp. 87-92, 2016.

[26] R. K. Ross, A. Paganini-Hill, P. C. Wan, and M. C. Pike, "Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin," Journal of the National Cancer Institute, vol. 92, no. 4, pp. 328-332, 2000.

[27] B. S. Appleton and T. C. Campbell, "Inhibition of aflatoxin-initiated preneoplastic liver lesions by low dietary protein," Nutrition and Cancer, vol. 3, no. 4, pp. 200-206, 1981.

[28] B. S. Appleton and T. C. Campbell, "Dietary protein intervention during the post-dosing phase of aflatoxin B1-induced hepatic preneoplastic lesion development," Journal of the National Cancer Institute, vol. 70, pp. 547-549, 1983.

[29] L. D. Youngman, "The sustained development of preneoplastic lesions depends on high protein intake," Nutrition and Cancer, vol. 18, no. 2, pp. 131-142, 1992.

[30] T. C. Campbell, "Cancer prevention and treatment by wholistic nutrition," Journal of Nature and Science, vol. 3, pp. 1-21, 2017.

[31] K. H. Kim and C. W. M. Roberts, "Targeting EZH2 in cancer," Nature Medicine, vol. 22, no. 2, pp. 128-134, 2016.

[32] C. Damaskos, S. Valsami, M. Kontos et al., "Histone deacetylase inhibitors: An attractive therapeutic strategy against breast cancer," Anticancer Reseach, vol. 37, no. 1, pp. 35-46, 2017.

[33] M. Uhlen, C. Zhang, S. Lee et al., "A pathology atlas of the human cancer transcriptome," Science, vol. 357, no. 6352, Article ID eaan2507, 2017.

[34] K. Lundstrom, "Epigenetics: new possibilities for drug discovery," Future Medicinal Chemistry, vol. 9, no. 5, pp. 437-441, 2017.

Patrick A. Riley [iD]

Totteridge Institute for Advanced Studies, The Grange, Grange Avenue, London N20 8AB, UK

Correspondence should be addressed to Patrick A. Riley;

Received 11 November 2017; Accepted 8 May 2018; Published 3 June 2018

Academic Editor: James L. Mulshine
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Riley, Patrick A.
Publication:Journal of Oncology
Date:Jan 1, 2018
Previous Article:RNA-seq Reveals the Overexpression of IGSF9 in Endometrial Cancer.
Next Article:The Association of Simultaneous Increase in Interleukin-6, C Reactive Protein, and Matrix Metalloproteinase-9 Serum Levels with Increasing Stages of...

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters